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Abstract
Limb-girdle muscular dystrophy type 2A (LGMD2A) is a recessive genetic disorder caused by mutations in calpain 3 (CAPN3).
Calpain 3 plays different roles in muscular cells, but little is known about its functions or in vivo substrates. The aim of this
study was to identify the genes showing an altered expression in LGMD2A patients and the possible pathways they are
implicated in. Ten muscle samples from LGMD2A patients with in which molecular diagnosis was ascertained were
investigated using array technology to analyze gene expression profiling as compared to ten normal muscle samples.
Upregulated genes were mostly those related to extracellular matrix (different collagens), cell adhesion (fibronectin), muscle
development (myosins and melusin) and signal transduction. It is therefore suggested that different proteins located or
participating in the costameric region are implicated in processes regulated by calpain 3 during skeletal muscle
development. Genes participating in the ubiquitin proteasome degradation pathway were found to be deregulated in
LGMD2A patients, suggesting that regulation of this pathway may be under the control of calpain 3 activity. As frizzled-
related protein (FRZB) is upregulated in LGMD2A muscle samples, it could be hypothesized that b-catenin regulation is also
altered at the Wnt signaling pathway, leading to an incorrect myogenesis. Conversely, expression of most transcription
factor genes was downregulated (MYC, FOS and EGR1). Finally, the upregulation of IL-32 and immunoglobulin genes may
induce the eosinophil chemoattraction explaining the inflammatory findings observed in presymptomatic stages. The
obtained results try to shed some light on identification of novel therapeutic targets for limb-girdle muscular dystrophies.
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Introduction
Limb-girdle muscular dystrophy type 2A (LGMD2A) is a
recessive genetic disorder caused by mutations in calpain 3
(CAPN3), a muscle-specific, calcium-dependent cystein protease.
Calpain 3 structure is similar to that of the ubiquitous calpains 1
and 2, but calpain 3 has specific regions (NS, IS1, and IS2) that
confer it special characteristics such as autocatalytic and nuclear
translocation capacity. Although calpain 3 was identified in 1989
[1], little is known about its function or its in vivo substrates. It has
been reported to play different roles in the cell. Calpain 3 has a
certain role in direct and indirect regulation of conventional
calpains by proteolytic degradation of calpains and calpastatin
respectively [2]. It may be involved in muscle contraction due to its
link to titin and to its regulation by calcium [3–7].
Calpain 3 was shown to be in complex with dysferlin, suggesting
a membrane homeostasis role of calpain 3 [8], and more recent
studies demonstrated that AHNAK, a novel component of the
dysferlin protein complex, serves as a direct substrate of calpain 3
in cell culture [9].
On the other hand, it has been confirmed that calpain 3 can cleave
the C-terminal portion of FLNC in vitro and suggested that FLNC
may be an in vivo substrate for calpain 3, functioning to regulate
protein-protein interactions with sarcoglycans. Thus, calpain-medi-
ated remodeling of cytoskeletal-membrane interactions, such as those
occurring during myoblast fusion and muscle repair, may involve
regulation of FLNC-sarcoglycan interactions [10].
Its presence in the nucleus has led to suggest that calpain 3 plays
an important role in regulation of transcription factors indirectly
controlling apoptotic processes [11,12]. Recent studies reported
that the antiapoptotic factor, cellular FLICE inhibitory protein (c-
FLIP), is NF-kB dependent and is only expressed when CAPN3 is
present [13]. However, other studies suggest that apoptosis may be
secondary to muscle damage and inflammatory response [14].
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Based on the observation of the C3 knockout (C3KO) mice, it
has been suggested that calpain 3 is necessary for ubiquitination
and acts upstream of the ubiquitination machinery [15].
Inflammatory cells have been detected in muscle tissue from
patients with mutations in the CAPN3 gene in early stages [16] as
happen in other distrophies. The role of inflammation in many
dystrophies seems to be unexplained, and it has been related to the
presence of signaling factors (cytokines) that withstand inflamma-
tory mechanisms and regulatory phenomena [17–19].
In this study, the RNA expression profiling in muscle from
biopsies of LGMD2A patients and control subjects were compared
in order to determine the potential functions and the pathways in
which calpain 3 is implicated.
Materials and Methods
Muscle samples and RNA processing
Muscle biopsies were taken from 10 LGMD2A patients (3
females and 7 males aged 13–48 years, mean age 29,5 years) and
10 controls (2 females and 8 males aged 22–84 years, mean age
50,2 years). Two out of the 10 LGMD2A patients showed an
inflammatory pattern with eosinophilic infiltrates in their biopsies.
For diagnostic purposes deltoid, quadriceps, and biceps muscle
specimens were collected using institutionally approved protocols
and after obtaining informed consent (Table 1). Muscle tissues
were snap frozen and stored at 280uC. Most of the 7 symptomatic
cases showed similar necrosis and regenerating phenomena (data
not available in one case).
The quality of all RNAs obtained from muscle biopsies
(RNAPlus, QBiogene) was verified using spectrophotometry and
the Bioanalyzer system (Agilent). All of them showed acceptable
quality and integrity (RIN above 7) to be eligible for the experiment.
All RNAs were reverse-transcribed, and biotinylated cRNA
probes were generated by in vitro transcription (Ambion, CA,
USA). Fragmented cRNA of each sample was hybridized
individually to human HG-U133A (22.283 probe sets) and HG-
U133B (22.645 probe sets) GeneChips (Affymetrix, Santa Clara,
California) in order to analyze the expression of 44.928 probes,
comprising more than 33.000 genes.
Data analysis
In-depth quality controls were performed to analyze the validity
of the hybridization processes in accordance with four criteria.
First, the correct presence of the signal corresponding to the spike
control BioB. Second, the expression ratio between the 39 and 59
ends of the housekeeping GAPDH should not exceed a value of
three. Third, the full percentage of presences detected by the
Affymetrix Detection algorithm for each array must be in the
range 40–60. And finally, the percentage of outlier probe sets
detected within each microarray should be less than 5%. All
hybridized arrays on the study met all four quality criteria,
demonstrating the reliability of data generated.
The hybridized arrays were scanned, and raw data were
extracted using the Microarray Analysis Suite 5.0 (MAS5;
Affymetrix). The raw data were normalized using RMA (Robust
Multichip Average) expression summary in Bioconductor [20].
RMA consists of three steps: a background adjustment, quantile
normalization, and finally summarization [21–23].
The sensitivity of microarray-generated data to noise from
experimental variables is well documented [24]. For the analysis,
the average values of each tested group (patients and controls)
were used in order to obtain the most homogeneous results, trying
to avoid variability between individual cases due to different
characteristics (genetic background, sex, age, muscles, mutations,
etc.). Two statistical methods were applied in order to distinguish
significant and substantial differential expression from noise and
variation due to either genetic heterogeneity or experimental
procedures.
First, in order to identify significantly different genes between
LGMD2A patients and normal controls, a geometric fold-change
analysis was used [24,25]. The threshold was set at a two-fold
change value. Using the criterion of fold-change implies that larger
fold changes are most likely to be real and no hypothesis is
assumed. Principal component analysis (PCA) was performed after
array normalization. PCA is a technique that summarizes a large
set of variables in a smaller set that retains the essential variance of
the original data set [26]. PCA derives an equivalent, uncorrelated
set of new variables from the original set of correlated variables
according to their contribution to a ranked set of principal
components [27].
Second, Class Comparison Difference Analyses were performed
using BRB-ArrayTools developed by Dr. Richard Simon and
BRB-ArrayTools Development Team. In order to identify probe
sets with significant intensity differences between disease classes, a
two-sample univariate t-test was applied to the unaffected control
data set vs. the LGMD2A data set. The use of p-values implies
hypothesis testing. It is assumed in the null hypothesis that there is
no fold change and then evidence was looked for to reject it using a
type-1 error. The threshold was set at p 0.001.
To minimize false positives, only the probe sets commonly
yielded by both methodologies were included into the final list of
genes differentially expressed in LGMD2A.
Moreover, as an additional supporting process, two machine
learning feature selection techniques were run. Symmetrical
uncertainty ranking [28] was first applied as an univariate
criterion to measure the worth of each probe set alone: this
computes the mutual information with respect to the class
phenotype and compensates for the bias of the information gain.
Correlation-based Feature Subset (CFS) selection [29], a multi-
variate feature selection that evaluates the merit of a probe set
subset by measuring the individual predictive power of each probe
set along with the redundancy within that subset, was then used.
CFS outputs a subset of features instead of individual relevances.
The same procedure was used to compare samples from
patients who were asymptomatic but had eosinophilic infiltrates in
their muscle biopsies (2 cases) and samples from healthy controls
(10 cases).
Microarray data have been submitted to the GEO (Gene
Expression Omnibus) public database (accession GSE11681).
Quantitative Real-Time PCR
To investigate the validity of array data, expression levels of the
differentially expressed genes were measured using the TaqMan
quantitative RT-PCR assay. Relative expression levels initially
determined with the cDNA microarrays were correlated to the
expression levels assessed using quantitative RT-PCR for each
patient sample.
Whereas microarrays identify target genes of interest among
thousands of genes, truly quantitative information relies on
quantitative RT-PCR. Some of the significantly regulated changes
found on the microarray could be replicated by quantitative RT-
PCR. Quantitative RT-PCR was performed using the 7900 HT
Fast Real-Time PCR System (Applied Biosystems). Because of the
limiting RNA amount isolated from muscle biopsies used for
microarray analysis, only a few samples (6 cases) were used for
confirmation with quantitative RT-PCR experiments.
The TaqMan Low Density Arrays (TLDA) were purchased
from Applied Biosystems, and the protocol recommended by the
Expression Profiling in LGMD2A
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manufacturer was used. Customer-designed TLDAs were used in
order to test a series of 63 genes. In order to select these genes,
genes with unknown function, hypothetical proteins, and open
reading frame regions were excluded. Gene families were
represented including only some of the members, such as
collagens, etc. Moreover, genes showing differential expression
profiling in the comparison between patients with eosinophilic
infiltrates and healthy controls were included in the TLDA, as well
as genes with expression variation in other studies.
Expression levels for all transcripts were determined relative to
the internal housekeeping control gene GAPDH in the TLDAs
which, as expected, did not demonstrate altered expression
according to microarray analysis.
In order to identify probe sets with significant intensity
differences, the method applied to the unaffected control data
set vs. the LGMD2A data set was Benjamini-Hochberg method
using Stat Miner program (Integromics).
Results
After having adjusted the background, normalized and
summarized the data, the fold change obtained generates a list
by magnitude of response. As a result of this method, the fold
change analysis identified 156 differentially expressed probe sets in
LGMD2A skeletal muscle compared to control skeletal muscle. Of
these, 92 were significantly overexpressed and 64 showed a
reduced expression in LGMD2A patients compared to the
unaffected controls.
PCA grouped together on the one hand patient samples and on
the other hand control samples and a greater variability was seen
among controls due to the heterogeneity of this group (Figure 1).
On the other hand, the additional statistical method used to
analyze the data, the Class Comparison Differences method,
applied a two-sample univariate t-test to the unaffected control
data set vs. the LGMD2A data set. This method identified 627
probe sets with a p value higher than 0.001.
However, the final list of genes comprised 86 probe sets (74
genes) commonly yielded by the two methodologies which were
differentially expressed in LGMD2A compared to unaffected
muscle biopsies. Of these 74 genes, 53 were overexpressed and 21
had a reduced expression in the LGMD2A patients and all the
genes were clustered into functional groups (Table 2). Transcripts
were classified according to different biological processes, as
obtained from LocusLink (www.ncbi.nlm.nih.gov/LocusLink/):
extracellular matrix proteins/phosphate transport, cell adhesion,
muscle development, transcription factors, signaling pathways,
metabolic process, transport, ubiquitin cycle, and other functions.
The additional supporting process, the Correlation-based
Feature Subset selection (CFS) [29] highlighted a set of 21 genes.
Of these 21 genes, 7 corresponded to the previously determined
group of 74 genes. In turn, Symmetrical Uncertainty Ranking
returned correlation coefficients higher than 0.5 for 24 genes
within the list. Note that the highest correlation was 0.816 when
the coefficient was constrained between 1 (maximum) and 0
(minimum). The average coefficient for the whole gene list was
0.36, with a standard deviation of 0.177.
Overview of expression profiling in LGMD2A muscles
Some transcript classes were of particular interest in this analysis
(Table 2). Most genes found to be dysregulated in LGMD2A were
genes grouped in the transcription factor category, and some of
them showed the lowest fold-change values obtained in the study
(FOS, EGR1). By contrast, genes showing the highest fold-change
values included extracellular matrix proteins, genes involved in
muscle development, and three additional genes with different
functions (FRZB, TFRC, and CAPN6).
As a whole, in most of the biologically classified processes, the
same trend to up- or downregulation was seen for all genes
involved in the same process. Genes associated with extracellular
matrix (collagen types I, III, V, and XV, and SPARC), cell
adhesion, muscle development (MYH3, MYL5 and ITGB1BP2),
signaling pathways, and ubiquitin cycle predominated among
Figure 1. Principal component analysis (PCA) of HG-U133A microarrays (A) and of HG-U133B microarrays (B) after normalization. P:
LGMD2A Patients. C: Healthy controls. Muscle specimens obtained from individuals of the same status showed the greatest similarities.
doi:10.1371/journal.pone.0003750.g001
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upregulated genes. However, all genes involved in metabolic
processes and transcription factors (except for the E2F8 gene) were
downregulated (Table 2).
On the other hand, upregulation of IGF1, which is a regulator
of somatic growth and cell proliferation, was seen in this study.
IGFa is an inducer of different pathways such as the phosphati-
dylinositol 3-kinase survival (through activation of AKT1, AKT2),
the calcineurin.mediated signaling pathways, and of GATA2
activation.
HERC1 and ANAPC1 are genes implicated in the ubiquitin
cycle and showed upregulation in LGMD2A muscle samples.
HERC1, ubiquitously expressed, is located in the cytosol in the
Golgi apparatus, stimulating guanine nucleotide, forming a
cytosolic ternary complex with clathrin and Hsp70, and is
involved in protein trafficking. ANAPC1 is a component of the
anaphase promoting complex/cyclosome (APC/C), a cell cycle-
regulated E3 ubiquitin ligase that controls progression through
mitosis and the G1 phase of the cell cycle.
There are two deregulated genes according to our results whose
cell location is the mitochondrion matrix, one of which is involved
in the metabolic process, ALDH2 (aldehyde dehydrogenase 2
family) (downregulated), while the other, the PPM2C gene (protein
phosphatase 2C, magnesium-dependent, catalytic subunit) (upre-
gulated) is implicated in protein amino acid dephosphorylation.
Expression changes in common with other muscular
dystrophies
Twenty four out of the 74 deregulated genes with altered
expression in LGMD2A were also deregulated in other muscular
dystrophies (DMD, a-SGD, FSHD, dysferlinopathies, Fukuyama-
type congenital muscular dystrophy, and laminin-a2 deficient
congenital muscular dystrophy) [24,30–35] (Table 2).
LGMD2A and eosinophil infiltration
A comparison was made between biopsies of control muscles (10
cases) and biopsies from two cases showing eosinophil infiltrates.
Results of this comparison are summarized in Table 3.
Genes involved in immune response such as IL-32, IGHG1,
and IGKC were upregulated, as well as CAPN6, while those
involved in chemotaxis or regulation of the protein kinase B
signaling cascade were downregulated in asymptomatic cases
comparing with controls.
Validation of microarray data by quantitative RT-PCR
The main correlation between the two assays is showed in Figure 2.
Real-time PCR was not only used to confirm the abnormal gene
expression profiles detected by microarray analysis, but also to better
define fold-change variations using a more sensitive approach. This
approach showed mean fold changes in expression levels directionally
similar to those determined by microarray analysis. Overall, fold
change was lower when the microarray approach was used compared
to real-time PCR (Table 2).
Discussion
The main correlation between the two assays, microarrays and
quantitative RT-PCR, was high for all genes, indicating a good
agreement between both assays for identification of deregulated
genes.
On the other hand, by means of the additional supporting
process, a high correlation degree among results was shown and it
provided more reliability to the final list of genes. Therefore,
results of the two machine learning approaches support the degree
of relevance of the 74 genes identified.
Calpain 3 was not abnormally regulated in the microarray study
(data not shown). While protein analysis usually shows an absence of
protein in patients, the microarray data did not reveal a reduction of
calpain 3 mRNA indicating that this primary genetic defect cannot
be identified by expression profiling. It is worthwhile mentioning
that the presence of different missense mutations in most of the
patients may explain this observation as well as the variability found
in the Western Blot including normal patterns [36].
In LGMD2A muscles, genes associated with ECM/membrane-
related, cell adhesion genes, muscle development genes, signaling
pathway genes, and ubiquitin cycle genes were upregulated
(Table 2).
Extracellular matrix
The general trend for structural genes to be expressed at higher
levels in patients could reflect a general upregulation of structural
genes in the mutant muscle, as previously reported for other types
of muscular dystrophies [37].
It is interesting to note that a large proportion of genes
associated to the extracellular matrix were probably upregulated
as a result of fibrotic infiltration. These genes include extracellular
matrix proteins such as collagen types I and III (the two major
collagens in the ECM), cell adhesion proteins such as CD9, CD44,
and fibronectin.
SPARC, overexpressed in the fibroblasts of skin biopsy
specimens obtained from patients with systemic sclerosis [38],
could be the factor involved in the interstitial fibrosis seen in
muscles of LGMD2A patients. It is a matricellular glycoprotein
that may modulate cell interaction within the ECM by binding to
both ECM structural components and growth factors.
Muscle development
Our results showed that MYH3 (myosin, heavy chain 3, skeletal
muscle, embryonic) is highly upregulated in samples from
LGMD2A patients. Expression of embryonic myosin heavy chain
is a hallmark of muscle regeneration after birth and a characteristic
marker of human muscular dystrophies. During normal human
development, expression is restricted to the embryonic period of
development [39]. This could indicate a failed muscular regener-
ation attempt to compensate a downstream injury.
Another upregulated gene is myosin light chain 1 slow A
(MLC1SA), a transcriptional regulator promoting muscle cell
proliferation expressed in both slow-twitch skeletal muscle and
non-muscle tissue. This gene showed a high individual correlation
with class phenotype (0.442), and was one of the seven genes
included in the CFS output. This fact flawlessly demonstrates its
importance not only from an individual point of view, but also
because of its potential interactions. MLC1SA is one of the two
phosphorylable regulatory light chains forming the myosin
complex. Cohen et al [40] found that MLC1SB (Accession Nu
P09542 in mice) was a substrate for calpain 3. To date, no
contractile proteins have been identified as in vivo substrates for
CAPN3. Identification of MLC1 as a potential substrate for
CAPN3 was of interest because, in a previous study, Kramerova et
al [15] demonstrated that CAPN3 regulates sarcomere remodeling
by acting upstream of the ubiquitin–proteasome system.
LGMD2A patients showed upregulation of the IGF-1 gene as
previously observed in other muscular dystrophies. Normal
skeletal muscle is able to efficiently repair itself in response to
injury. IGF-1 has been implicated as a factor that may affect many
steps in gene expression control, including cell proliferation,
differentiation, and degradation processes. IGF-1 is a peptide that
has been shown to have anabolic effects on muscle cells. This
action can be explained based on the molecular signaling events
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initiated by its receptor, a tyrosine kinase activated on IGF-1
binding, and transmitted through a cascade of intracellular events,
leading to a general increase in protein synthesis [41,42].
Integrin b1 binding protein (ITGB1BP2 = melusin), also
upregulated in LGMD2A muscles, is present in a costamere-like
pattern consisting of two rows flanking a-actinin at Z line. Melusin
expression is upregulated during in vitro differentiation of the
C2C12 murine myogenic cell line, and is regulated during in vivo
skeletal muscle development [43]. Upregulation of the melusin
gene may alter a process that is tightly controlled in muscle
development, leading to inadequate muscle differentiation and
maturation. The generalized inhibition of terminal stages of
myogenic differentiation in C3KO myotubes affects at least two
events: sarcomere formation and integrin isoform replacement
[44]. During myogenesis, two isoforms of b1 integrin are
expressed: b1A is expressed in myoblasts and is downregulated
during myogenesis, while b1D appears after fusion and eventually
displaces b1A in mature myotubes [45]. Neither b1A nor b1D
were cleaved by CAPN3, suggesting that changes in the level of
integrin isoforms are not a direct result of calpain 3 absence [44].
Ubiquitin cycle and protein degradation
It is still unclear whether CAPN3 directly cleaves proteins to
make them available for ubiquitination or whether the effect of
CAPN3 is indirect (i.e. through regulation of other proteins
involved in ubiquitination) [15]. In LGMD2A muscle samples, the
HERC1 and ANAPC1 genes involved in the ubiquitin cycle are
upregulated, suggesting that their regulation may be under the
control of calpain 3.
Moreover, Ono et al [46] found proteolysis of proteasome
regulatory subunit RPS6A by calpain 3, which may indicate that the
ubiquitin-proteasome system is subject to regulation by calpain.
As ubiquitination tags proteins for degradation, decreased
ubiquitination may lead to excessive accumulation of the proteins
that should otherwise be degraded. This in turn could trigger a cell
stress response, one manifestation of which is upregulation of heat
shock proteins [15]. According to the reported data, the DnaJ
(Hsp40) homolog, subfamily A member 4 (DNAJA4), that showed
upregulation, may regulate the chaperone function of Hsp70
proteins [47].
Signaling pathways
The protein coded by HERC1, upregulated in LGMD2A
patients, has a C-terminal HECT (homologous to E6-AP C-
terminus) domain, which suggests that it has an ubiquitin ligase
activity.
b-catenin plays a critical role in many cellular and morphogenic
processes by performing two distinct functions: in the nucleus, it
acts as a mandatory coactivator of TCF/LEF transcription factors
in response to Wnt signaling during both embryonic development
and adult muscle regeneration, while at the cell membrane, b-
catenin associates with the cadherin complex that links adhesion
molecules to the cytoskeleton. In both cases, the concentration of
b-catenin has been shown to be tightly regulated through
ubiquitin-mediated degradation [44].
Two distinct ubiquitin ligase complexes control b-catenin levels
in cytoplasm and at the membrane [48]. Ubiquitination and
degradation of the cytosolic pool of b-catenin are under the
control of Wnt signaling. Degradation of the membrane pool of b-
catenin in skeletal muscle is mediated by the Ozz-E3 ubiquitin
ligase complex [49]. Thus, it may be suggested that membrane b-
catenin is indirectly regulated by CAPN3. It should also be noted
that Trim32, found mutated in limb-girdle muscular dystrophy
type 2H, is another putative E3-ubiquitin-ligase [50].
On the other hand, frizzled-related protein (FRZB) is
upregulated in LGMD2A muscle samples. It could therefore be
hypothesized that b-catenin regulation is also altered at the Wnt
signaling pathway, leading to an abnormal myotube fusion or
incorrect myogenesis.
Deregulation of mitochondrial genes
In our results, the mitochondrial genes found to be deregulated
were ALDH2 and PPM2C. ALDH2 was downregulated in patient
samples and is implicated in the glycolysis/gluconeogenesis
pathway. On the contrary, expression of the PPM2C mitochon-
drial gene was upregulated in our study. Protein phosphatase 1J
(PPM1J_mouse, PP2C family) was found to be an in vivo substrate
for calpain 3 [40].
In later stages of the disease, the muscle pathology is
characterized mainly by the presence of lobulated fibers (LF),
which are composed of misaligned myofibrils that form a lobular
pattern, in addition to fiber size variation and interstitial fibrosis.
Lobulated muscle fibers reflect an abnormal spatial distribution of
the intermyofibrillar mitochondria network [51]. In C3KO mice,
abnormal A-bands were seen, suggesting a role for calpain 3 in
correct formation of sarcomeres or maintenance of sarcomere
alignment [14].
mRNA expression profiles were specifically altered in LGMD2A
muscles with lobulated fibers Keira et al [52]. Genes encoding for
extracellular matrix (ECM)/membrane-related, cytoskeletal, or
sarcomeric proteins were also upregulated in LF muscles.
According to these results, identification of these mitochondrial
proteins suggests that CAPN3 may be involved in mitochondrial
protein turnover.
Common genes with altered expression in different
muscular dystrophies
According to Table 2, LGMD2A can be characterized as an
active fibrotic disease with suppressed muscle regeneration, since
LGMD2A cases share upregulation of the extracellular matrix
Figure 2. Comparison between expression data obtained from
microarray experiments and data obtained from quantitative
RT-PCR.
doi:10.1371/journal.pone.0003750.g002
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(ECM) components with congenital muscular dystrophy cases and
share downregulation of the transcription factors with Duchenne
muscular dystrophies.
In muscles from patients with Duchenne muscular dystrophy,
upregulated genes were mostly those related to immune response,
sarcomeric, ECM, and cell growth, whereas downregulated genes
were associated to energy metabolism, transcription/translation,
signaling, and proteasomes [32].
c-fos and c-jun proteins have been described as showing strong
cytoplasmic expression related to the degeneration process
occurring in Duchenne and Becker muscular dystrophies [53].
However our results contradict the previously published results
and they showed a strong downregulation of c-fos and c-jun in our
samples.
Recently Gan et al [54] reported that Dishevelled (Dvl) and c-
Jun form a complex with b-catenin-T-cell factor 4 (TCF-4) on the
promoter of Wnt target genes and regulate gene transcription. c-
Jun mediates Dvl association with the functional TCF-b-catenin
complex and functions as a key component of Wnt signaling in vivo.
Since genes coding for proteins in this pathway are dysregulated in
LGMD2A patients, it may be suggested that the downregulation
of c-jun and other transcription factors observed in LGMD2A
patients are regulated in an indirect way by calpain 3.
TFRC (transferrin receptor) and VLDLR (very low density
lipoprotein receptor) are upregulated in LGMD2A patients as
occurred in FSHD muscles [33]. Transferrin is a key myoblast
trophic factor, initially promoting myoblast proliferation and
subsequently supporting myogenic differentiation. However,
TXNIP (thioredoxin-interacting protein) is downregulated in
LGMD2A muscles and was also downregulated in FSHD samples
[33]. Since TXNIP acts as an oxidative stress mediator, this
finding is consistent with the enhanced vulnerability to oxidative
stress seen in LGMD2A, as observed in FSHD myoblasts [33].
Many of the genes deregulated in facioscapulohumeral muscular
dystrophy (FSHD) are involved in myogenesis, cell differentiation,
and cell-cycle control.
According to the available information, it could be suggested
that FSHD shared the greatest quantity of differentially expressed
genes and the deregulation tendencies (up/downregulation) are
the same and in a similar range of variation. However it would be
difficult to establish any correlation given that in the FSHD, even
in patients with the same deletion fragment, high variability of
impairment and of muscle affectation grade is observed.
Therefore, the data depend enormously on the place and on the
moment that biopsy has been taken.
S100A6 (calcyclin) and S100A8 (calgranulin A), dysregulated in
LGMD2A muscles, are involved in various intracellular and
extracellular regulatory activities [55]. Upregulation of S100A6
expression was seen also in LGMD2B and as in other muscular
dystrophies, the structural defect causes a general membrane
instability that leads to an altered uptake of calcium ions into the
muscle fibers [31]. Since calpain 3 interacts with dysferlin and
AHNAK, a role of calpain 3 in membrane homeostasis has been
suggested [8,9]. The increased Ca2+ concentration probably
influences expression of various signaling molecules whose
transcription is sensitive to calcium concentration.
Dysferlin was not abnormally regulated in LGMD2A patients in
the microarray study. The value obtained for the expression of the
DYSF gene did not fulfil the established criteria to be considered
as differently expressed (data not shown).
In this study mRNA levels are analysed, not protein quantities.
Even if the protein is reduced in the Western Blot, this reduction
may not be regulated at a transcriptional level, it may happen at a
post-translation level. Since calpain 3 was shown to be in complex
with dysferlin and it has been demonstrated that AHNAK, a novel
component of the dysferlin protein complex, serves as a direct
substrate of calpain 3 in cell culture, the lack of one of these
proteins may justify the reduction of the other.
As described in previous works [31] while western blotting tests
showed a reduction or the absence of dysferlin protein in most
LGMD2B patients, the microarray data showed a reduction of
dysferlin mRNA for some of the patients analysed. This could be
due to the different types of mutations of the gene that affects the
translation efficiency of the mRNA or the stability of the protein.
Additionally, while protein analysis usually shows an absence of
protein in the C57BL/10.SJL-Dysf mice, the microarray data did
not reveal a reduction of dysferlin mRNA indicating that this
primary genetic defect cannot be identified by expression profiling
[37]. Moreover, it has been observed that neither calpain-3 nor
caveolin was consistently reduced in dysferlinopathies.
The vast majority of upregulated genes in Fukuyama-type
congenital muscular dystrophy (FCMD) and laminin-a2 deficient
congenital muscular dystrophy (MDC1A) encode extracellular
matrix components, presumably related to fibrotic change.
However, mature muscle components were extremely downreg-
ulated in congenital muscular dystrophies [34].
Muscle regeneration is also a process that depends on the
skeletal muscle basement membrane. Basement membrane is
thought to not only maintain cell integrity but also to mediate
signal transmission in cell differentiation, growth, attachment,
survival, polarity, proliferation, and apoptosis [56,57]. It is
hypothesized that upregulation of ECM genes might arise from
signal transduction defects due to basement membrane dysfunc-
tion. It is possible that muscle fibers keep high transcription levels
of ECM to create basement membrane components [34].
Costameric proteins can interact with many components of both
the sarcolemma and cytoskeleton. Different publications support a
role for the costamere/Z-disk axis in mechanotransduction, the
dynamic process through which mechanical stimuli are sensed by
muscle cells and converted into biochemical responses [57].
Based on our results and since collagens, melusin and
fibronectin, were deregulated, we may hypothesize that upregula-
tion of ECM genes found in LGMD2A patients may result from
signal transduction defects due to basement membrane dysfunc-
tion. Calpain 3 recognizes a wide range of substrates, including
cytoskeletal proteins and myofibrillar proteins [40,46]. These
cytoskeletal proteins and matrix proteins contribute to cell shape,
mechanical resistance, and morphological integrity of muscle cells,
and are part of a complex network of filaments and tubules that
transmit mechanical and chemical stimuli between cells. The
cytoskeleton is not only involved in cell stability and integrity, but
also plays a significant role in signal transmission from the cell
membrane to the nucleus.
LGMD2A and eosinophilic infiltrations
Presence of eosinophilic cells has recently been detected in muscle
tissue from patients with mutations in the CAPN3 gene [16].
In our study, IL-32 was upregulated in LGMD2A patients with
eosinophilic infiltrates (Table 3). Although IL-32 does not share
sequence homology with known cytokine families, IL-32 induces
various cytokines, human TNFa, and IL-8 in THP-1 monocytic
cells. IL-32 activates typical cytokine signal pathways of nuclear
factor-kappa B (NF-kB) and p38 mitogen-activated protein kinase
[58]. The neutrophil-derived proteinase 3 (PR3) was identified as a
putative IL-32 receptor [59], supporting the possibility that IL-32
upregulation in muscle may be chemoattractant for eosinophilic
cells.
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Eosinophilia has also been reported as a prominent feature of
the necrotic phase in dystrophin-deficient mdx mice. This study
suggested that eosinophilia was promoted by at least perforin-
dependent cytotoxicity of effector T cells and T-cell production of
interleukin-5 (IL-5) [60]. However these authors concluded that
some eosinophilia of mdx muscle is independent from perforin-
mediated processes and that it may be suggested that a similar
mechanism of calpain 3 could act in this process.
Inflammatory features may be seen in some muscular
dystrophies, such as facioscapulohumeral muscular dystrophy
[17] and dysferlinopathies [19]. Moreover, a Becker muscular
dystrophy presenting eosinophilic inflammatory myopathy was
described by Weinstock et al [18].
Although the comparison between gene expression profiles
between LGMD2A with and without eosinophilia would be
interesting, it was not possible to perform. The methods used needed
a higher quantity of samples to obtain significant results. Moreover,
when a PCA plot was performed for LGMD2A patients only
(including cases with and without eosinophilia), no different groups
were created and this may be due to the low sample number too.
It seems that the comparison between asymptomatic patients
with eosinophilia with control samples is more indicated to shed
some light onto the initial mechanism that triggers the eosinophilic
cell attraction to muscle. The comparison between asymptomatic
patients and controls allows a clearer view due to a lower
interfering expression variation.
In a first approach asymptomatic cases were considered as
affected and were included into the patient group in the general
analysis. These cases were included in the affected group due to
their abnormal muscle biopsy pattern. Additionally reinforcing this
decision, the PCA plots clustered together the LGMD2A case with
or without eosinophilia.
Finally in an additional analysis, however, it was decided to
consider them as a different group compared to the controls in
order to obtain information about eosinofilic attraction in the early
stage of the disease.
Conclusions
In conclusion, upregulated genes were mostly those related to
extracellular matrix, cell adhesion, sarcomeric proteins, and signal
transduction. It is therefore suggested that different proteins
located at or participating in the costameric region are involved in
processes regulated by calpain 3 during skeletal muscle develop-
ment. Upregulation of these proteins may indicate a compensatory
attempt of the muscle, and since most of these genes are also
upregulated in other dystrophic processes, upregulation might be
relatively nonspecific.
It was also found that genes participating in the ubiquitin
proteasome degradation pathway are deregulated in LGMD2A
patients, which suggests that regulation of this pathway may be
under the control of calpain 3 activity.
Finally, the upregulation of IL-32 and immunoglobulin genes
may cause the eosinophil chemoattraction observed in the
inflammatory findings in presymptomatic stages. This upregula-
tion seems to disappear when the disease progresses. However,
they might be quite specific markers for the disease.
Though samples taken from different muscles could add
variability to the results of the expression array analysis,
correlation of the results with the quantitative RT-PCR results
gave strength to the findings. Gene expression profiling is
presented as a useful approach to mine new data and hopefully
open new perspectives for muscular disorders, shedding some light
on identification of novel therapeutic targets for limb-girdle
muscular dystrophies.
Looking ahead, each of these methods should be individually
analyzed in the animal model and in cell models.
This analysis gives a total of 24 genes that may be considered as
potential diagnostic or evolutionary biomarkers of the disease.
However, this question will not be solved until the predictive value
of these markers is proved in a series of patients with different
evolutive status and secondly until the consistency of the results in
different muscles and different laboratories is proved.
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